

()

HDL

(/ /)

NCEP(ATP III)

/ /

(ECG -IHD)

/

/ /

/

/ P= /)

(OR= / P= /)

(OR= / P< /)

(OR = / CI: /

(OR= / P= /)

HDL

:

*

**

.()

HDL

.()

NHANES III³

.()

" "

.()

ATP

.()

" III¹

.()

NCEP²

.()

)

(

HDL

)

(

(

(

/

.()

ATP III-NCEP

.()

.()

:

: I

: II

³ NHANES III: National Health And Nutrition Examination Survey III

¹ ATP III: Adult Treatment Panel III

² NCEP: National Cholesterol Education Program

« Standimeter »

BMI .()

ECG .

Selectra 2 autoanalyzer (Vital " " specific,The Netherlands)

colorimetric method)
(enzymatic glucose oxidase
(Pars Azmun Inc;Tehran, Iran)

HDL

(oxidase phenol aminoantipyrine cholesterol)

)
enzymatic – method glycerol -3 phosphate
(oxidase phenol aminoantipyrine
Friedman) LDL

(Formula

National cholesterol Education)

Program's Adult Treatment panel III "
" (ATP III

« WHO MONICA »

: HDL

/)

(/

:

:

(/)

(/)

/)

/

(IHD-ECG)

(.)

(P < /

/

(.)

ATP(III)

ECG

(/)

(/)

(/)

IHD ECG

: (

*

Chi-square

()

" Two-Tailed test"

P > /

(OR= / CI= / / P= /)}

IHD-ECG

/ - / P= /)

{ (OR= / CI=)

(

IBM

(OR= /)

(OR= /)

SPSS 9.05 (SPSS Inc;Chicago,IL)

(OR= /)

HDL

(/)	(/)	(/)	(/)	(/)	(/)
(/)	(/)	(/)	(/)	(/)	(/)
(/)	(/)	(/)	(/)	(/)	(/)
(/)	(/)	(/)	(/)	(/)	(/)
(/)	(/)	(/)	(/)	(/)	(/)

(

/	/	/	
/	/	/	
/	/	/	
/	/	/	
/	/	/	()
/	/	/	()

P.value	C.I	OR
/	(/ /)	/
/	(/ /)	/
/	(/ /)	/
/	(/ /)	/
/	(/ /)	/

ATP III

()

/

/

-
 -
 " " " "
 " NCEP" " WHO" .()
 .() /
 / /
 NCEP
 -
 WHO
 -
 .()
 " "
 WHO .(P< /)
 .()
 Bruneck study
 .()
 /
 .() /
 .()
 Atherosclerosis Risk in (OR= / P< /)
 Communities Study
 " ATP III"

. ()

COX
/

(OR= /) . / . ()
. () (OR = /)

. (OR = /) . ()

" " . ()

OR= /) .
. (OR= /

HDL

. ()

ATP III

HDL

Kaunas

. ()

References:

1. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. *Circulation* 2003;108:420-425.
2. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001;285:2486-2497.
3. Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. *Endocrinol Metab Clin N Am* 2004;33:351-375.
4. Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome. *Diabetes Care* 2003;26:1251-1257.
5. Azizi F, Salehi P, Etemadi A, et al. Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. *Diab Res Clin Pract* 2003;61:29-37.
6. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States Adults. *Circulation* 2004;110:1245-1250.
7. Wong ND. Intensified screening and treatment of the metabolic syndrome for cardiovascular risk reduction. *Prev Cardiol* 2005;8:47-54.
8. Ninomiya JK, L Italien G, Criqui MH, et al. Association of the metabolic syndrome with history of myocardial infarction and stroke in the third national health and nutrition examination survey. *Circulation* 2004;109:42-46.
9. Vitarius JA. The metabolic syndrome and cardiovascular disease. *Mount Sinai J Med* 2005;72:257-262.
10. Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. *Diabetes Care* 2004;27:2444-2449.
11. Balkau B, Vernay M, Mhamdi L, et al. The incidence and persistence of the NCEP metabolic syndrome. The French D. E.S.I.R. study. *Diabet Metab* 2003;29:526-32.
12. Hunt KJ, Resendez RG, Williams K, et al. San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. *Circulation* 2004;110:1251-1257.
13. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. *JAMA* 2002;288:2709-2716.
14. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. *Diabetes Care* 2005;28:385-390.
15. Zeller M, Steg PG, Ravisy J, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. *Arch Intern Med* 2005;165:1192-8.
16. Cerniauskiene LR, Reklaitiene R, Luksiene DI, et al. Association of metabolic syndrome with ischemic heart disease among middle-aged Kaunas population. *Medicina* 2005;41:435-41.
17. Lindblad U, Langer RD, Wingard DL, et al. Metabolic syndrome and ischemic heart disease in elderly men and women. *Am J Epidemiol* 2001;153:481-9.